A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-enhancing, IDH1 Mutant, Low-grade Glioma. (AG120-881-C-001)

Clinical Trial Grant

Duke Scholars

Principal Investigator Katherine Barnett Peters Neurosurgery, Neuro-Oncology

Administered By

Duke Cancer Institute

Awarded By

Agios Pharmaceuticals, Inc.

Start Date

March 20, 2018

End Date

March 31, 2023

Administered By

Duke Cancer Institute

Awarded By

Agios Pharmaceuticals, Inc.

Start Date

March 20, 2018

End Date

March 31, 2023